Novo escalates Lilly false advertising suit with planned bid to halt comparative ads

Novo Nordisk is escalating its legal battle against Eli Lilly over its GLP-1 drug marketing, notifying a federal court that it plans to seek a preliminary injunction that would stop its obesity riv | The company is targeting Lilly ad campaigns that cite what Novo calls “outdated” clinical trials comparing Lilly’s drugs with Ozempic and Wegovy.

Raccontata davalor.globo.comexpansion.comlavanguardia.comchannelnewsasia.comendpoints.newsaxios.comirishtimes.combiopharmadive.comeconomictimes.indiatimes.comfiercepharma.com